BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27438146)

  • 1. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
    Ye H; Zhang X; Chen Y; Liu Q; Wei J
    Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets.
    Guo J; Liu H; Zheng J
    Nucleic Acids Res; 2016 Jan; 44(D1):D1011-7. PubMed ID: 26516187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.
    Srihari S; Singla J; Wong L; Ragan MA
    Biol Direct; 2015 Oct; 10():57. PubMed ID: 26427375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of potential synthetic lethal genes to p53 using a computational biology approach.
    Wang X; Simon R
    BMC Med Genomics; 2013 Sep; 6():30. PubMed ID: 24025726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Literature-based translation from synthetic lethality screening into therapeutics targets: CD82 is a novel target for
    Yang HT; Chien MY; Chiang JH; Lin PC
    Comput Struct Biotechnol J; 2022; 20():5287-5295. PubMed ID: 36212540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSNK1E/CTNNB1 are synthetic lethal to TP53 in colorectal cancer and are markers for prognosis.
    Tiong KL; Chang KC; Yeh KT; Liu TY; Wu JH; Hsieh PH; Lin SH; Lai WY; Hsu YC; Chen JY; Chang JG; Shieh GS
    Neoplasia; 2014 May; 16(5):441-50. PubMed ID: 24947187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma.
    Szczurek E; Misra N; Vingron M
    Int J Cancer; 2013 Nov; 133(9):2123-32. PubMed ID: 23629686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Candidate Human Synthetic Lethal Interactions Through siRNA and Quantitative Imaging-Based Approaches.
    Jeusset LM; McManus KJ
    Methods Mol Biol; 2021; 2381():151-173. PubMed ID: 34590275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
    Wang X; Zhang Y; Han ZG; He KY
    Medicine (Baltimore); 2016 Feb; 95(8):e2697. PubMed ID: 26937901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Link synthetic lethality to drug sensitivity of cancer cells.
    Wang R; Han Y; Zhao Z; Yang F; Chen T; Zhou W; Wang X; Qi L; Zhao W; Guo Z; Gu Y
    Brief Bioinform; 2019 Jul; 20(4):1295-1307. PubMed ID: 29300844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network.
    Liu L; Chen X; Hu C; Zhang D; Shao Z; Jin Q; Yang J; Xie H; Liu B; Hu M; Ke K
    Sci Rep; 2018 May; 8(1):8440. PubMed ID: 29855504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the landscape of synthetic lethal interactions in liver cancer.
    Yang C; Guo Y; Qian R; Huang Y; Zhang L; Wang J; Huang X; Liu Z; Qin W; Wang C; Chen H; Ma X; Zhang D
    Theranostics; 2021; 11(18):9038-9053. PubMed ID: 34522226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SL-scan identifies synthetic lethal interactions in cancer using metabolic networks.
    Zangene E; Marashi SA; Montazeri H
    Sci Rep; 2023 Sep; 13(1):15763. PubMed ID: 37737478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response.
    Pinoli P; Srihari S; Wong L; Ceri S
    BMC Bioinformatics; 2021 May; 22(1):250. PubMed ID: 33992077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates.
    Zhang F; Wu M; Li XJ; Li XL; Kwoh CK; Zheng J
    J Bioinform Comput Biol; 2015 Jun; 13(3):1541002. PubMed ID: 25669329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
    Chang JG; Chen CC; Wu YY; Che TF; Huang YS; Yeh KT; Shieh GS; Yang PC
    Oncotarget; 2016 Nov; 7(45):73664-73680. PubMed ID: 27655641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients.
    Markowska M; Budzinska MA; Coenen-Stass A; Kang S; Kizling E; Kolmus K; Koras K; Staub E; Szczurek E
    Sci Rep; 2023 Apr; 13(1):7049. PubMed ID: 37120674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of synthetic lethality by meta-analysis of genetic interactions, functions, and pathways in yeast and human cancer.
    Wu M; Li X; Zhang F; Li X; Kwoh CK; Zheng J
    Cancer Inform; 2014; 13(Suppl 3):71-80. PubMed ID: 25452682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
    Dando I; Cordani M; Donadelli M
    IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.